Tentou Pharmaceutical

Tentou Pharmaceutical is a clinical-stage biopharmaceutical company based in Japan that specializes in the development of treatments for rare diseases. The company employs a drug repositioning strategy, utilizing its proprietary platform to identify new therapeutic applications for existing drugs with established safety profiles. Tentou's lead candidate, T-001, is a small molecule ATP-sensitive potassium channel opener currently being evaluated for the treatment of Congenital Hyperinsulinism (CHI). By focusing on repositioning, the company aims to reduce the time and cost associated with traditional drug discovery while addressing significant unmet medical needs. Tentou is supported by prominent venture capital firms and maintains a strong focus on pediatric rare endocrine disorders.